Evidence map›Paper›PMID 34895296›Full record

ArticleTrials2021

Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST-MST): protocol for identification of novel biomarkers via neurophysiology.

Zafiris J Daskalakis, Shawn M McClintock, Itay Hadas, Elisa Kallioniemi, Reza Zomorrodi, Alanah Throop, Lucy Palmer, Faranak Farzan, Kevin E Thorpe, Carol Tamminga and 1 more

2 registry-linked trialsOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03191058 nacompletednot on this map

Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST - MST)

TypeinterventionalSponsorUniversity of Texas Southwestern Medical CenterRan2018 to 2024Enrolled239ConditionsDepression, Unipolar Depression, Treatment Resistant DepressionArmsMagnetic Seizure Therapy, Electroconvulsive Therapy
NCT06581302 narecruitingnot on this mapstarted 2024, after this paper: background citation

Accelerated 100Hz Magnetic Seizure Therapy for Psychotic Disorders

TypeinterventionalSponsorShanghai Jiao Tong University School of MedicineRan2024 to 2025Enrolled50ConditionsPsychotic DisordersArmsMagnetic seizure therapy by Magnetic stimulator, Antipsychotic medications (such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc)
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2023
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Zafiris J DaskalakisDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA. zdaskalakis@health.ucsd.edu.
Shawn M McClintockDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Itay HadasDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
Elisa KallioniemiDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Reza ZomorrodiTemerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Alanah ThroopDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
Lucy PalmerDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Faranak FarzanSchool of Mechatronic Systems Engineering, Simon Fraser University, Surrey, British Columbia, Canada.
Kevin E ThorpeApplied Health Research Centre, Li Ka Shing Knowledge Institute of St. Michael's, Toronto, Ontario, Canada.
Carol TammingaDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Daniel M BlumbergerTemerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
The University of Texas Southwestern Medical Center · USUniversity of California, San Diego · USCentre for Addiction and Mental Health · CAPublic Health Ontario · CASimon Fraser University · CA

Funding

Confirmatory Safety and Efficacy Trial of Magnetic Seizure Therapy for DepressionR01MH112815 · NIMH · CENTRE FOR ADDICTION AND MENTAL HEALTH · PI BLUMBERGER, DANIEL M., DASKALAKIS, ZAFIRIS J. · 2017 to 2023
$7.4M
NIMH NIH HHS 1R01-MH112815NIMH NIH HHS R01 MH112815
6 · The paper itself

Abstract

backgroundElectroconvulsive therapy (ECT) is the most effective treatment for treatment-resistant depression (TRD), especially for acute suicidal ideation, but the associated cognitive adverse effects and negative stigma limit its use. Another seizure therapy under development is magnetic seizure therapy (MST), which could potentially overcome the restrictions associated with ECT with similar efficacy. The neurophysiological targets and mechanisms of seizure therapy, however, remain poorly understood. METHODS/

designThis neurophysiological study protocol is published as a companion to the overall Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST-MST) protocol that describes our two-site, double-blind, randomized, non-inferiority clinical trial to develop MST as an effective and safe treatment for TRD. Our aim for the neurophysiological component of the study is to evaluate two biomarkers, one to predict remission of suicidal ideation (primary outcome) and the other to predict cognitive impairment (secondary outcome). Suicidal ideation will be assessed through cortical inhibition, which according to our preliminary studies, correlates with remission of suicidal ideation. Cortical inhibition will be measured with simultaneous transcranial magnetic stimulation (TMS) and electroencephalography (EEG), TMS-EEG, which measures TMS-evoked EEG activity. Cognitive adverse effects associated with seizure therapy, on the contrary, will be evaluated via multiscale entropy analysis reflecting the complexity of ongoing resting-state EEG activity. DISCUSSION: ECT and MST are known to influence cortical inhibition associated with depression, suicidal ideation severity, and clinical outcome. Therefore, evaluating cortical inhibition and brain temporal dynamics will help understand the pathophysiology of depression and suicidal ideation and define new biological targets that could aid clinicians in diagnosing and selecting treatments. Resting-state EEG complexity was previously associated with the degree of cognitive side effects after a seizure therapy. This neurophysiological metric may help clinicians assess the risk for adverse effects caused by these useful and effective treatments.

trial registrationClinicalTrials.gov NCT03191058 . Registered on June 19, 2017.

Indexed as

Depressive Disorder, Treatment-ResistantNeurophysiologyBiomarkersDepressionEquivalence Trials as TopicHumansRandomized Controlled Trials as TopicSeizuresBiomarkersCortical inhibitionElectroconvulsive therapyElectroencephalographyMagnetic seizure therapyNeurophysiologyTranscranial magnetic stimulationTreatment-resistant depression

Identifiers

PMID34895296
PMCPMC8666076
OpenAlexW4200576155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.